Literature DB >> 32247173

Molecular signatures of atherosclerotic plaques: An up-dated panel of protein related markers.

S Eslava-Alcon1, M J Extremera-García1, A González-Rovira1, A Rosal-Vela2, M Rojas-Torres1, L Beltran-Camacho1, I Sanchez-Gomar2, M Jiménez-Palomares1, J A Alonso-Piñero1, R Conejero3, E Doiz3, J Olarte4, A Foncubierta-Fernández5, E Lozano6, F J García-Cozar1, M Rodríguez-Piñero3, G Alvarez-Llamas7, M C Duran-Ruiz8.   

Abstract

Atherosclerosis remains the leading cause of ischemic syndromes such as myocardial infarction or brain stroke, mainly promoted by plaque rupture and subsequent arterial blockade. Identification of vulnerable or high-risk plaques constitutes a major challenge, being necessary to identify patients at risk of occlusive events in order to provide them with appropriate therapies. Clinical imaging tools have allowed the identification of certain structural indicators of prone-rupture plaques, including a necrotic lipidic core, intimal and adventitial inflammation, extracellular matrix dysregulation, and smooth muscle cell depletion and micro-calcification. Additionally, alternative approaches focused on identifying molecular biomarkers of atherosclerosis have also been applied. Among them, proteomics has provided numerous protein markers currently investigated in clinical practice. In this regard, it is quite uncertain that a single molecule can describe plaque rupture, due to the complexity of the process itself. Therefore, it should be more accurate to consider a set of markers to define plaques at risk. Herein, we propose a selection of 76 proteins, from classical inflammatory to recently related markers, all of them identified in at least two proteomic studies analyzing unstable atherosclerotic plaques. Such panel could be used as a prognostic signature of plaque instability. Crown
Copyright © 2020. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Biomarkers; Proteomics; Secretome; Vulnerable plaques

Mesh:

Substances:

Year:  2020        PMID: 32247173     DOI: 10.1016/j.jprot.2020.103757

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  3 in total

Review 1.  Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery.

Authors:  Bohdan B Khomtchouk; Yoon Seo Lee; Maha L Khan; Patrick Sun; Deniel Mero; Michael H Davidson
Journal:  Expert Opin Drug Discov       Date:  2022-03-08       Impact factor: 7.050

2.  Atherosclerotic Pre-Conditioning Affects the Paracrine Role of Circulating Angiogenic Cells Ex-Vivo.

Authors:  Sara Eslava-Alcon; Mª Jesús Extremera-García; Ismael Sanchez-Gomar; Lucía Beltrán-Camacho; Antonio Rosal-Vela; Javier Muñoz; Nuria Ibarz; Jose Angel Alonso-Piñero; Marta Rojas-Torres; Margarita Jiménez-Palomares; Almudena González-Rovira; Rosario Conejero; Esther Doiz; Manuel Rodriguez-Piñero; Rafael Moreno-Luna; Mª Carmen Durán-Ruiz
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

3.  The serum of COVID-19 asymptomatic patients up-regulates proteins related to endothelial dysfunction and viral response in circulating angiogenic cells ex-vivo.

Authors:  Rafael Moreno-Luna; Mª Carmen Durán-Ruiz; Lucía Beltrán-Camacho; Sara Eslava-Alcón; Marta Rojas-Torres; Daniel Sánchez-Morillo; Mª Pilar Martinez-Nicolás; Victoria Martín-Bermejo; Inés García de la Torre; Esther Berrocoso; Juan Antonio Moreno
Journal:  Mol Med       Date:  2022-04-09       Impact factor: 6.354

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.